Stockscreener 앱 받기
35.42
1.09%
-0.39
시간 외 거래:
35.42
전일 마감가:
$35.81
열려 있는:
$35.5
하루 거래량:
1.57M
Relative Volume:
2.05
시가총액:
$2.02B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
-8.9671
EPS:
-3.95
순현금흐름:
$-330.11M
1주 성능:
-9.10%
1개월 성능:
-35.15%
6개월 성능:
-16.56%
1년 성능:
+53.60%
1일 변동 폭
$35.13
$36.30
1주일 범위
$35.13
$44.46
52주 변동 폭
$20.96
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
35.42 | 2.02B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 3.9%Time to Sell? - MarketBeat
Agios Pharmaceuticals' SWOT analysis: mitapivat potential drives stock outlook - Investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Agios gains EU orphan drug status for sickle cell treatment By Investing.com - Investing.com UK
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease - The Manila Times
Agios' Mitapivat Secures Coveted EU Orphan Drug Status for Sickle Cell Disease Treatment - StockTitan
Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 83 RS Rating - Investor's Business Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% HigherStill a Buy? - MarketBeat
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
State Street Corp Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Zacks Research Issues Negative Forecast for AGIO Earnings - MarketBeat
Fmr LLC Increases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals director David Scadden sells $9,256 in stock By Investing.com - Investing.com Australia
Agios Pharmaceuticals director David Scadden sells $9,256 in stock - Investing.com
Agios Pharmaceuticals Enters Oversold Territory (AGIO) - Nasdaq
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com
Agios Pharmaceuticals Shares Cross Below 200 DMA - Nasdaq
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Analyst Ratings For Agios Pharmaceuticals - Benzinga
Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank - Yahoo Finance
Frazier Life Sciences Management L.P. Acquires 172,180 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug - Yahoo! Voices
Alpha Thalassemia Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Agios Pharma, Novo Nordisk, Bristol-Myers Squibb, Genmedicn Biopharma - Barchart
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug - Yahoo! Voices
ASH 2024: Agios’ mitapivat checks off efficacy; liver toxicity a concern - BioWorld Online
Agios reports results from late-stage study of its thalassemia treatment (NASDAQ:AGIO) - Seeking Alpha
Oncology Market Overview and Leading Players: Daiichi Sankyo - openPR
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat - br.ADVFN.com
Agios Phase 3 Trial Breakthrough: Mitapivat Shows 3x Better Results for Thalassemia Treatment - StockTitan
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock? - MSN
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios - Yahoo Finance
Parkman Healthcare Partners LLC Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals: A Long Overdue Follow Up (NASDAQ:AGIO) - Seeking Alpha
(AGIO) Trading Advice - Stock Traders Daily
Erste Asset Management GmbH Acquires Shares of 2,184,900 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Caligan Partners LP Has $25.76 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Bellevue Group AG - MarketBeat
PDT Partners LLC Sells 18,545 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Vestal Point Capital LP Invests $33.77 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Summit Partners Public Asset Management LLC Acquires Shares of 101,730 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Intech Investment Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Fisher Asset Management LLC Grows Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by Loomis Sayles & Co. L P - MarketBeat
AGIO (Agios Pharmaceuticals) 3-Year EPS without NRI Growth Rate : -9.90% (As of Sep. 2024) - GuruFocus.com
Beta-thalassemia Market is Predicted to Exhibit Remarkable Growth During the Forecast Period, asserts DelveInsight | Phoenicia, EdiGene, Imara, Agios, Ionis - Barchart
Alpha Thalassemia Pipeline Insights 2024: Therapies, Clinical - openPR
Beta-thalassemia Market is Predicted to Exhibit Remarkable - openPR
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Agios Pharmaceuticals Inc 주식 (AGIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Dec 11 '24 |
Sale |
46.28 |
200 |
9,256 |
15,483 |
| Washburn Theodore James Jr. | Principal Accounting Officer |
Nov 08 '24 |
Sale |
56.09 |
772 |
43,301 |
813 |
| Ballal Rahul D. | Director |
Nov 07 '24 |
Option Exercise |
25.99 |
10,000 |
259,900 |
17,992 |
| Ballal Rahul D. | Director |
Nov 08 '24 |
Option Exercise |
25.99 |
10,000 |
259,900 |
17,992 |
| Ballal Rahul D. | Director |
Nov 08 '24 |
Sale |
58.19 |
10,000 |
581,911 |
7,992 |
| Ballal Rahul D. | Director |
Nov 07 '24 |
Sale |
53.52 |
10,000 |
535,236 |
7,992 |
| Burns James William | Chief Legal Officer |
Nov 07 '24 |
Sale |
52.21 |
21,752 |
1,135,775 |
15,700 |
2.88%
2.65%
자본화:
|
볼륨(24시간):